Table 2:

Select studies evaluating the role of local therapy for colorectal lung metastases

Author	Treatment modality	Study design	Number of patients	Mean follow-up	Local control	Progression-free survival	Overall survival	Comments
Davini et al20	Surgery	Retrospective	210	56 months	7.14% resection margin recurrence	NR	1-year: 95% 3-year: 74% 5-year: 54%	76% with single lung metastasis
Fournel et al21	Surgery	Retrospective	306	3.06 years	NR	3-year: 38.9% 5-year: 28.3% 7-year: 22.7%	3-year: 77.8% 5-year: 59.0% 7-year: 56.9%	64% with unilateral disease
Okumura et al22	Surgery	Retrospective	785	65 months (median)	NR	5-year: 37.1%	5-year: 68.1%	74% with single lung metastasis
Renaud et al23	Surgery	Retrospective	574	62 months (median)	21% 5-year pulmonary recurrence-free survival	NR	5-year: 58%	50% with single lung metastasis
Lencioni et al29	Radiofrequency ablation	Phase II, single arm	106, colorectal in 53	15 months	88%	NR	1-year: 89% 2-year: 66%	Pneumothorax in 20% of procedures
De Baère et al30	Radiofrequency ablation	Prospective database	566, colorectal in 293	35.5 months (median)	Local tumor progression per patient: 1-year: 10.4% 2-year: 15.5% 3-year: 17.5% 4-year: 18.1%	1-year: 40.2% 2-year: 23.3% 3-year: 16.4% 4-year: 13.1%	1-year: 92.4% 2-year: 79.4% 3-year: 67.7% 4-year: 58.9% 5-year: 51.5%	For CRC patients, size >2 cm and ≥3 lesions associated with worse OS; Pneumothorax in 67% of procedures requiring chest tube in 58%
Jung et al32	SABR	Retrospective	50	42.8 months (median)	1-year: 88.7% 3-year: 70.6%	3-year: 24.0%	3-year: 64.0%	No grade 3+ Toxicity reported
Jingu et al31	SABR	Retrospective	93	28 months (median)	3-year: 65.2% 5-year: 56.2%	NR	3-year: 55.9% 5-year: 42.7%	2 patients with grade 3+ toxicity
Kinj et al33	SABR	Retrospective	53	33 months (median)	1-year: 79.8% 2-year: 78.2%	1-year: 29.2% 2-year: 14.6%	1-year: 83.8% 2-year: 69.3% 5-year: 58.3%	No grade 3+ Toxicity reported

Abbreviations: CRC, colorectal cancer; NR, not reported; OS, overall survival; SABR, stereotactic ablative radiotherapy